FEATURED EDITORIAL
A number of patients report receiving half a pill in a blister pack of their prescribed medicine. The initial sponsor reaction is to place the problem at an external partner’s production or packaging line. But overall responsibility lies with the sponsor, and the true extent of the problem is hard to detect. Enter AI. Says Damiano Dragone, a long-term Quality expert, AI and biopharma professionals throughout the supply chain can join in a new “logic and creativity" to improve our industry on behalf of patients.
- Your 7 Decisions To Make Before MES Configuration
- CDMOs Co-Author The RNA Ecosystem
- The Orange Book's Blind Spot: Process Stability And Capability
- Are You Falling Behind On Intelligent Pharmaceutical Manufacturing?
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- Your CDMO Can Make It, But Can Your Market Afford It?
GUEST COLUMNISTS
-
Are You Falling Behind On Intelligent Pharmaceutical Manufacturing?
With a focus on small molecule drug product manufacture, let's take a closer look at the efficiencies gained through closed-loop control, PAT, digital twins, and more.
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
-
US Pharma Reshoring: The Full Policy Timeline
As policy shifts and manufacturing investments reshape pharma supply chains, capacity constraints and global dependencies persist. Explore the implications for long-term resilience.
PHARMA OUTSOURCING WHITE PAPERS
-
The Importance Of Quality In Raw Material Selection
Learn how to select high-quality raw materials for cell-based manufacturing in this exploration of the criticality of raw materials, from preclinical development to commercialization.
-
Accelerated API Manufacturing: Combining All Process Development Stages
During early-stage development, utilize the key considerations outlined in this paper to avoid common pitfalls and expedite the transition from molecule to market.
-
Comprehensive Characterization Strategies For Antibody-Drug Conjugates
As ADCs grow more complex and expand beyond oncology, robust characterization is essential. Learn how analytical strategies connect structure to function and identify critical quality attributes.
-
A Powerful Non-Destructive Tool For Tablet Characterization
Discover how X-ray micro-CT provides vital, non-destructive analysis of a tablet’s internal 3D physical structure. This structural insight is essential for troubleshooting defects and confirming performance.
-
Unlocking Durable Allogeneic Cell Therapy
Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.
-
Achieving Rapid, High-Titer Expression For Next-Generation Biologics
This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Smarter Lead Selection And Faster Representative Material
- APAC Scaling AAV manufacturing to 1000 L: strategies for robust and reproducible production
- Scaling AAV Manufacturing To 1000 L: Strategies For Robust And Reproducible Production
- Design Verification Done Right: Smarter Strategies For Prefillable Syringes
- IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic